{"id":"aleglitazar-metformin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL519504","moleculeType":"Small molecule","molecularWeight":"437.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Aleglitazar activates PPARα and PPARγ receptors, enhancing the transcription of genes involved in glucose and lipid metabolism. Metformin inhibits hepatic glucose production and increases insulin sensitivity in peripheral tissues.","oneSentence":"Aleglitazar, a PPARα/γ agonist, and metformin, a biguanide, work together to improve insulin sensitivity and glucose uptake in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:35.039Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01691846","phase":"PHASE3","title":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10","conditions":"Diabetes Mellitus Type 2","enrollment":200},{"nctId":"NCT01871415","phase":"PHASE3","title":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-05","conditions":"Diabetes Mellitus Type 2","enrollment":7},{"nctId":"NCT01680978","phase":"PHASE2","title":"A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10","conditions":"Diabetes Mellitus Type 2","enrollment":18},{"nctId":"NCT01691989","phase":"PHASE3","title":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12","conditions":"Diabetes Mellitus Type 2","enrollment":197},{"nctId":"NCT01729403","phase":"PHASE2","title":"A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12","conditions":"Diabetes Mellitus Type 2","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"aleglitazar+metformin","genericName":"aleglitazar+metformin","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aleglitazar, a peroxisome proliferator-activated receptor alpha agonist, was studied in combination with metformin for the treatment of type 2 diabetes mellitus. The combination of aleglitazar and metformin was compared to a placebo and aleglitazar alone in a randomized, double-blind, placebo-controlled clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}